The bicyclam AMD3100 story

Nature Reviews Drug Discovery

Volumn 2, Issue 7, 2003, Pages 581-587

  De Clercq, Eric ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); ALPHA N ACETYLNONA DEXTRO ARGININE AMIDE; AMD 070; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIMONIOTUNGSTATE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CYCLAM; JM 1493; JM 1590; JM 1657; JM 2763; JM 2820; JM 2987; METAL OXIDE; RECEPTOR BLOCKING AGENT; T 140; TC 14012; UNCLASSIFIED DRUG; GLYCOPROTEIN GP 120; HETEROCYCLIC COMPOUND;

ANTIVIRAL ACTIVITY; ARTICLE; CANCER; DRUG DESIGN; DRUG IMPURITY; DRUG ISOLATION; DRUG STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATORY DISEASE; NONHUMAN; PRIORITY JOURNAL; STEM CELL MOBILIZATION; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; HEART; MOLECULAR GENETICS; NEOPLASM; PHYSIOLOGY; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; ANTI-HIV AGENTS; HEART; HETEROCYCLIC COMPOUNDS; HIV ENVELOPE PROTEIN GP120; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS; RECEPTORS, CXCR4;

EID: 0038681342     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1134     Document Type: Article

References (50)

1. Rozenbaum, W. et al. Antimoniotungstate (HPA 23) treatment of three patients with AIDS and one with prodrome. Lancet 1, 450-451 (1985).
2. De Clercq, E. Antiviral therapy for human immunodeficiency virus infections. Clin. Microbiol. Rev. 8, 200-239 (1995).
3. De Clercq, E. Antiviral metal complexes. Metal-Based Drugs 4, 173-192 (1997).
4. Yamamoto, N. et al. Mechanism of anti-human immunodeficiency virus action of polyoxometalates, a class of broad-spectrum antiviral agents Mol. Pharmacol. 42, 1109-1117 (1992).
5. Song, R. et al. Anti-HIV activities of anionic metalloporphyrins and related compounds. Antivir. Chem. Chemother. 8, 85-97 (1997).
6. De Clercq, E. et al. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc. Natl Acad. Sci. USA 89, 5286 5290 (1992).
7. De Clercq, E. et al. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob. Agents Chemother. 38, 668-674 (1994).
8. De Vreese, K. et al. The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding. Antiviral Res. 29, 209-219 (1996).
9. Esté, J. et al. Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1. Antiviral Res. 29, 297-307 (1996).
10. De Vreese, K. et al. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. J. Virol. 70, 689-696 (1996).
11. De Vreese, K., Van Nerum, I., Vermeire, K., Anné, J. & De Clercq, E. Sensitivity of human immunodeficiency virus to bicyclam derivatives is influenced by the three-dimensional structure of gp120. Antimicrob. Agents Chemother. 41, 2616-2620 (1997).
12. Schols, D. et al. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J. Exp. Med. 186, 1383-1388 (1997).
13. Schols, D., Esté, J. A., Henson, G. & De Clercq, E. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusion/CXCR-4. Antiviral Res. 35, 147-156 (1997).
14. Donzella, G. A. et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nature Med. 4, 72-77 (1998).
15. De Clercq, E. Hamao Umezawa Memorial Award Lecture 'An Odyssey in the Viral Chemotherapy Field'. Int. J. Antimicrob. Agents 18, 309-328 (2001).
16. De Clercq, E. Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists. Mol. Pharmacol. 57, 833-839 (2000).
17. Esté, J. et al. Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor Mol. Pharmacol. 55, 67-73 (1999).
18. Esté, J. et al. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4. J. Virol. 73, 5577-5585 (1999).
19. Schols, D., Esté, J. A., Cabrera, C. & De Clercq, E. T-Cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1(contains mutations in the envelope gp120 but does not show a switch in coreceptor use. J. Virol. 72, 4032-4037 (1998).
20. Schols, D. & De Clercq, E. The simian immunodeficiency virus mnd(GB-1) strain uses CXCR4, not CCR5, as coreceptor for entry in human cells. J. Gen. Virol. 79, 2203-2205 (1998).
21. Murakami, T. et al. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J. Exp. Med. 186, 1389-1393 (1997).
22. Fujii, N., Nakashima, H. & Tamamura, H. The therapeutic potential of CXCR4 antagonists in the treatment of HIV. Expert Opin. Investig. Drugs 12, 185-195 (2003).
23. Doranz, B. J. et al. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J. Exp. Med. 186, 1395-1400 (1997).
24. Ichiyama, K. et al. A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc. Natl Acad. Sci. USA 100, 4185-4190 (2003).
25. Schols, D. et al. Anti-HIV activity profile of AMD070, an orally bioavailable CXCR4 antagonist. The Sixteenth International Conference on Antiviral Research, Savannah, Georgia, USA, 27 April-1 May 2003. Antiviral Res. 57, A39 (2003).
26. Datema, R. et al. Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry. Antimicrob. Agents Chemother 40, 750-754 (1996).
27. Hendrix, C. W. et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob. Agents Chemother. 44, 1667-1673 (2000).
28. Schols, D. et al. AMD-3100, a CXCR4 antagonist, reduced HIV viral load and X4 virus levels in humans. 9th Conf. on Retroviruses and Opportunistic Infections Seattle, Washington, USA, 24-28 February. Abs, p. 53, no. 2 (2002).
29. Doranz, B. J. et al. Safe use of the CXCR4 inhibitor ALX40-4C in humans. AIDS Res. Hum. Retroviruses 17, 475-486 (2001).
30. Dale, D.C. et al. AMD-3100 alone increases human peripheral blood stem cells which engraft in NOD/SCID mice and also enhances the activity of G-CSF. Int. Soc. Hematol. Meeting Quebec, Canada, 5-9 July. Abstracts (2002).
31. + progenitor cells from normal human volunteers with AMD-3100, a CXCR4 antagonist, and G-CSF Am. Soc. Hematol. Annu. Meeting Philadelphia, Pennsylvania, USA, 6-10 December. Abs. no. 404. Blood 100, 109a (2002).
32. Liles, W. C. et al. Leukocytosis and mobilization of pluripotent hematopoietic progenitor cells in healthy volunteers induced by single dose administration of AMD-3100, a CXCR4 antagonist. Am. Soc. Hematol. Annu. Meeting Orlando, Florida, USA, 7-11 December. Abs. no. 3071. Blood 98, 737a (2001).
33. Petit, I. et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nature Immunol. 3, 687-694 (2002).
34. 262 of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100. Mol. Pharmacol. 60, 164-173 (2001).
35. Gerlach, L. O., Skerlj R. T., Bridger, G. J. & Schwartz, T. W. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J. Biol. Chem. 276, 14153-14160 (2001).
36. Gerlach, L. O. et al. Metal ion enhanced binding of AMD3100 to Asp262 in the CXCR4 receptor. Biochemistry 42, 710-717 (2003).
37. Hatse, S., Princen, K., Bridger, G., De Clercq, E. & Schols, D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett. 527, 255-262 (2002).
38. Berger, E. A., Murphy, P. M. & Farber, J. M. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17, 657-700 (1999).
39. Nagasawa, T. et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382, 635-638 (1996).
40. Tachibana, K. et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 393, 591-594 (1998).
41. Broxmeyer, H. E., Hangoc, G , Cooper, S. & Bridger, G. Interference of the SDF-1/CXCR4 axis in mice with AMD3100 induces rapid high level mobilization of hematopoietic progenitor cells, and AMD3100 acts synergistically with G-CSF and MIP-1 to mobilize progenitors. Am. Soc. Hematol. Annu. Meeting Orlando, Florida, USA, 7-11 December. Abs. 3371. Blood 98, 811a (2001).
42. Broxmeyer, H. E. et al. AMD3100, an antagonist of CXCR4 and mobilizer of myeloid progenitor cells, is a potent mobilizer of competitive repopulating long term marrow self-renewing stem cells in mice. American Soc. Hematol. Annual Meeting Philadelphia, Pennsylvania, USA, 6-10 December Abs. 2397. Blood 100, 609a (2002).
43. Iwakura, A. et al. AMD-3100, a CXCR4 antagonist, augments incorporation of bone marrow-derived endothelial progenitor cells into sites of myocardial neovascularization. American Soc. Hematol. Annual Meeting Philadelphia, Pennsylvania, USA, 6-10 December Abs. 1127. Blood 100, 293a (2002).
44. Matthys, P. et al. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-(receptor-deficient mice. J. Immunol. 167, 4686-4692 (2001).
45. Lukacs, N. W., Berlin, A., Schols, D., Skerlj, R. T & Bridger, G. J. AMD3100, a CXCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity. Am. J. Pathol. 160, 1353-1360 (2002).
46. Müller, A. et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56 (2001).
47. Juarez, J., Bradstock, K. F., Gottlieb, D. J. & Bendall, L. J. Antagonists of the chemokine receptor CXCR4 block chemotaxis and inhibit stromal dependent proliferation of acute lymphoblastic leukemia cells. American Soc. Hematol. Annual Meeting Philadelphia, Pennsylvania, USA, 6-10 December. Abs. 3015. Blood 100, 762a (2002).
48. Paul, S. et al. In vitro and preclinical activity of the novel AMD3100 CXCR4 antagonist in lymphoma models. American Soc. Hematol. Annual Meeting, Philadelphia, Pennsylvania, USA, 6-10 December Abs. 2276. Blood 100, 579a (2002).
49. Koshiba, T. et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin. Cancer Res. 6, 3530-3535 (2000).
50. Scotton, C. J. et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res. 62, 5930-5938 (2002).